William Schierding

Dr. William Schierding

Liggins Institute, The University of Auckland, 1023 Auckland, New Zealand
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2010 in Nature
Verified
Journal Article
Open access
PDF file
LDLi Ding
Li Ding
MEMatthew J. Ellis
Matthew J. Ellis
SLShunqiang Li
Shunqiang Li
DLDavid E. Larson
David E. Larson
KCKen Chen
Ken Chen
EMElaine R. Mardis
Elaine R. Mardis
Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primary tumour. The metastasis contained two de novo mutations and a large deletion not present in the primary tumour, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumour mutations and displayed a mutation enrichment pattern that resembled the metastasis. Two overlapping large deletions, encompassing CTNNA1, were present in all three tumour samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour.

10 June 2012 in Nature
Verified
Journal Article
Open access
PDF file
MEMatthew J Ellis
Matthew J Ellis
LDLi Ding
Li Ding
DSDong Shen
Dong Shen
JLJingqin Luo
Jingqin Luo
VSVera J Suman
Vera J Suman
EMElaine R Mardis
Elaine R Mardis
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1) previously linked to haematopoietic disorders. Mutant MAP3K1 was associated with luminal A status, low-grade histology and low proliferation rates, whereas mutant TP53 was associated with the opposite pattern. Moreover, mutant GATA3 correlated with suppression of proliferation upon aromatase inhibitor treatment. Pathway analysis demonstrated that mutations in MAP2K4, a MAP3K1 substrate, produced similar perturbations as MAP3K1 loss. Distinct phenotypes in oestrogen-receptor-positive breast cancer are associated with specific patterns of somatic mutations that map into cellular pathways linked to tumour biology, but most recurrent mutations are relatively infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing.

3 July 2012 in Genome Research
Verified
Journal Article
Open access
PDF file
NDNathan D. Dees
Nathan D. Dees
QZQunyuan Zhang
Qunyuan Zhang
CKCyriac Kandoth
Cyriac Kandoth
MWMichael C. Wendl
Michael C. Wendl
William SchierdingWilliam Schierding
William Schierding
LDLi Ding
Li Ding
Massively parallel sequencing technology and the associated rapidly decreasing sequencing costs have enabled systemic analyses of somatic mutations in large cohorts of cancer cases. Here we introduce a comprehensive mutational analysis pipeline that uses standardized sequence-based inputs along with multiple types of clinical data to establish correlations among mutation sites, affected genes and pathways, and to ultimately separate the commonly abundant passenger mutations from the truly significant events. In other words, we aim to determine the Mutational Significance in Cancer (MuSiC) for these large data sets. The integration of analytical operations in the MuSiC framework is widely applicable to a broad set of tumor types and offers the benefits of automation as well as standardization. Herein, we describe the computational structure and statistical underpinnings of the MuSiC pipeline and demonstrate its performance using 316 ovarian cancer samples from the TCGA ovarian cancer project. MuSiC correctly confirms many expected results, and identifies several potentially novel avenues for discovery.

7 August 2014 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
CMChristopher A. Miller
Christopher A. Miller
BWBrian S. White
Brian S. White
NDNathan D. Dees
Nathan D. Dees
MGMalachi Griffith
Malachi Griffith
JWJohn S. Welch
John S. Welch
LDLi Ding
Li Ding
The sensitivity of massively-parallel sequencing has confirmed that most cancers are oligoclonal, with subpopulations of neoplastic cells harboring distinct mutations. A fine resolution view of this clonal architecture provides insight into tumor heterogeneity, evolution, and treatment response, all of which may have clinical implications. Single tumor analysis already contributes to understanding these phenomena. However, cryptic subclones are frequently revealed by additional patient samples (e.g., collected at relapse or following treatment), indicating that accurately characterizing a tumor requires analyzing multiple samples from the same patient. To address this need, we present SciClone, a computational method that identifies the number and genetic composition of subclones by analyzing the variant allele frequencies of somatic mutations. We use it to detect subclones in acute myeloid leukemia and breast cancer samples that, though present at disease onset, are not evident from a single primary tumor sample. By doing so, we can track tumor evolution and identify the spatial origins of cells resisting therapy. Sequencing the genomic DNA of cancers has revealed that tumors are not homogeneous. As a tumor grows, new mutations accumulate in individual cells, and as these cells replicate, the mutations are passed on to their offspring, which comprise only a portion of the tumor when it is sampled. We present a method for identifying the fraction of cells containing specific mutations, clustering them into subclonal populations, and tracking the changes in these subclones. This allows us to follow the clonal evolution of cancers as they respond to chemotherapy or develop therapy resistance, processes which may radically alter the subclonal composition of a tumor. It also gives us insight into the spatial organization of tumors, and we show that multiple biopsies from a single breast cancer may harbor different subclones that respond differently to treatment. Finally, we show that sequencing multiple samples from a patient's tumor is often critical, as it reveals cryptic subclones that cannot be discerned from only one sample. This is the first tool that can efficiently leverage multiple samples to identify these as distinct subpopulations of cells, thus contributing to understanding the biology of the tumor and influencing clinical decisions about therapy.

27 March 2019 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
DHDaniel Sik Wai Ho
Daniel Sik Wai Ho
William SchierdingWilliam Schierding
William Schierding
MWMelissa Wake
Melissa Wake
RSRichard Saffery
Richard Saffery
Justin Martin O'sullivanJustin Martin O'sullivan
Justin Martin O'sullivan
In the past decade, precision genomics based medicine has emerged to provide tailored and effective healthcare for patients depending upon their genetic features. Genome Wide Association Studies have also identified population based risk genetic variants for common and complex diseases. In order to meet the full promise of precision medicine, research is attempting to leverage our increasing genomic understanding and further develop personalized medical healthcare through ever more accurate disease risk prediction models. Polygenic risk scoring and machine learning are two primary approaches for disease risk prediction. Despite recent improvements, the results of polygenic risk scoring remain limited due to the approaches that are currently used. By contrast, machine learning algorithms have increased predictive abilities for complex disease risk. This increase in predictive abilities results from the ability of machine learning algorithms to handle multi-dimensional data. Here, we provide an overview of polygenic risk scoring and machine learning in complex disease risk prediction. We highlight recent machine learning application developments and describe how machine learning approaches can lead to improved complex disease prediction, which will help to incorporate genetic features into future personalized healthcare. Finally, we discuss how the future application of machine learning prediction models might help manage complex disease by providing tissue-specific targets for customized, preventive interventions.

6 September 2019 in Science Advances
Verified
Journal Article
Open access
AAAlexessander Couto Alves
Alexessander Couto Alves
NSN. Maneka G. De Silva
N. Maneka G. De Silva
VKVille Karhunen
Ville Karhunen
USUlla Sovio
Ulla Sovio
SDShikta Das
Shikta Das
ECEarly Growth Genetics (EGG) Consortium
Early Growth Genetics (EGG) Consortium
Longitudinal data find a new variant controlling BMI in infancy and reveal genetic differences between infant and adult BMI.